Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells
Само за регистроване кориснике
2016
Аутори
Srdić-Rajić, TatjanaNikolić, Katarina
Cavić, Milena
Đokić, Ivana
Gemović, Branislava
Perović, Vladimir
Veljković, Nevena
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Imidazoline I1 receptor signaling is associated with pathways that regulate cell viability leading to varied cell-type specific phenotypes. We demonstrated that the antihypertensive drug rilmenidine, a selective imidazoline I1 receptor agonist, modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells. Rilmenidine acts through a mechanism which involves deactivation of Ras/MAP kinases ERK, p38 and JNK. Moreover, rilmenidine renders K562 cells, which are particularly resistant to chemotherapeutic agents, susceptible to the DNA damaging drug doxorubicin. The rilmenidine co-treatment with doxorubicin reverses G2/M arrest and triggers apoptotic response to DNA damage. Our data offer new insights into the pathways associated with imidazoline I1 receptor activation in K562 cells suggesting rilmenidine as a valuable tool to deepen our understanding of imidazoline I1 receptor signal...ing in hematologic malignancies and to search for medicinally active agents.
Извор:
European Journal of Pharmaceutical Sciences, 2016, 81, 172-180Издавач:
- Elsevier Science BV, Amsterdam
Финансирање / пројекти:
- Примена EIIP/ISM биоинформатичке платформе у откривању нових терапеутских таргета и потенцијалних терапеутских молекула (RS-MESTD-Basic Research (BR or ON)-173001)
DOI: 10.1016/j.ejps.2015.10.017
ISSN: 0928-0987
PubMed: 26598394
WoS: 000367787700021
Scopus: 2-s2.0-84946239745
Институција/група
PharmacyTY - JOUR AU - Srdić-Rajić, Tatjana AU - Nikolić, Katarina AU - Cavić, Milena AU - Đokić, Ivana AU - Gemović, Branislava AU - Perović, Vladimir AU - Veljković, Nevena PY - 2016 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2578 AB - Imidazoline I1 receptor signaling is associated with pathways that regulate cell viability leading to varied cell-type specific phenotypes. We demonstrated that the antihypertensive drug rilmenidine, a selective imidazoline I1 receptor agonist, modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells. Rilmenidine acts through a mechanism which involves deactivation of Ras/MAP kinases ERK, p38 and JNK. Moreover, rilmenidine renders K562 cells, which are particularly resistant to chemotherapeutic agents, susceptible to the DNA damaging drug doxorubicin. The rilmenidine co-treatment with doxorubicin reverses G2/M arrest and triggers apoptotic response to DNA damage. Our data offer new insights into the pathways associated with imidazoline I1 receptor activation in K562 cells suggesting rilmenidine as a valuable tool to deepen our understanding of imidazoline I1 receptor signaling in hematologic malignancies and to search for medicinally active agents. PB - Elsevier Science BV, Amsterdam T2 - European Journal of Pharmaceutical Sciences T1 - Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells VL - 81 SP - 172 EP - 180 DO - 10.1016/j.ejps.2015.10.017 ER -
@article{ author = "Srdić-Rajić, Tatjana and Nikolić, Katarina and Cavić, Milena and Đokić, Ivana and Gemović, Branislava and Perović, Vladimir and Veljković, Nevena", year = "2016", abstract = "Imidazoline I1 receptor signaling is associated with pathways that regulate cell viability leading to varied cell-type specific phenotypes. We demonstrated that the antihypertensive drug rilmenidine, a selective imidazoline I1 receptor agonist, modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells. Rilmenidine acts through a mechanism which involves deactivation of Ras/MAP kinases ERK, p38 and JNK. Moreover, rilmenidine renders K562 cells, which are particularly resistant to chemotherapeutic agents, susceptible to the DNA damaging drug doxorubicin. The rilmenidine co-treatment with doxorubicin reverses G2/M arrest and triggers apoptotic response to DNA damage. Our data offer new insights into the pathways associated with imidazoline I1 receptor activation in K562 cells suggesting rilmenidine as a valuable tool to deepen our understanding of imidazoline I1 receptor signaling in hematologic malignancies and to search for medicinally active agents.", publisher = "Elsevier Science BV, Amsterdam", journal = "European Journal of Pharmaceutical Sciences", title = "Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells", volume = "81", pages = "172-180", doi = "10.1016/j.ejps.2015.10.017" }
Srdić-Rajić, T., Nikolić, K., Cavić, M., Đokić, I., Gemović, B., Perović, V.,& Veljković, N.. (2016). Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells. in European Journal of Pharmaceutical Sciences Elsevier Science BV, Amsterdam., 81, 172-180. https://doi.org/10.1016/j.ejps.2015.10.017
Srdić-Rajić T, Nikolić K, Cavić M, Đokić I, Gemović B, Perović V, Veljković N. Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells. in European Journal of Pharmaceutical Sciences. 2016;81:172-180. doi:10.1016/j.ejps.2015.10.017 .
Srdić-Rajić, Tatjana, Nikolić, Katarina, Cavić, Milena, Đokić, Ivana, Gemović, Branislava, Perović, Vladimir, Veljković, Nevena, "Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells" in European Journal of Pharmaceutical Sciences, 81 (2016):172-180, https://doi.org/10.1016/j.ejps.2015.10.017 . .